1 completed. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
Follow IL-15 plus: new trials by email Literature Review of IL-15 plus trials Research Report on IL-15 plus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) IL-15 plus, alemtuzumab - T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL) | Phase 1 | Completed | National Cancer Institute (NCI) | 11 | 2017-01-19 | 2022-04-29 |
Leukemia, Prolymphocytic, T-Cell (1) · Leukemia-Lymphoma, Adult T-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Lymphoma, T-Cell, Peripheral (1)
National Cancer Institute (NCI) (1)
United States (1)